Active — Not RecruitingNot Applicable

Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B

Germany, Netherlands9 participantsStarted 2021-03-18

Plain-language summary

This is an open-label, extension study enrolling patients who have successfully completed all assessments in Study CT-AMT-060-01 (Years 1-5). Assessment phase will begin at Visit 36 (the first clinical visit in this extension study, approximately 5.5 years after the initial dosing visit Study CT-AMT-060-01) and go to Visit 45 (10-years post-dosing in Study CT-AMT-060-01).

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects with congenital hemophilia B who completed Study CTAMT-060-01 * Able to provide informed consent following receipt of verbal and written information about the trial. Exclusion Criteria: * Enrolled subjects will have already been assessed based on the exclusion criteria for Study CT-AMT-060-01.